GlassScriptPhysician profile
Susan Kay Clavette
NPI 1770903114
$9,037.79
in general payments reported to CMS, 2019-2025
29 companies · $1,833 in 2025
The $1,833 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,554 · 2022: $1,653 · 2023: $1,744 · 2024: $2,254 · 2025: $1,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,615 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,614.86 |
| Education | $216.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,432.41 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $1,057.66 | 2021-2025 | Trintellix |
| Lundbeck LLC | $1,009.55 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $687.28 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $648.60 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $529.95 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $435.44 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $361.45 | 2021-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $310.04 | 2022-2025 | Austedo Xr, Austedo Xr |
| Harmony Biosciences LLC | $287.82 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $272.27 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.83 | 2021-2022 | |
| Corium, LLC | $226.30 | 2022-2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $188.13 | 2022 | |
| Merck Sharp & Dohme LLC | $159.26 | 2021-2023 | Belsomra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $152.55 | 2023-2024 | Ingrezza |
| Collegium Pharmaceutical, INC. | $143.71 | 2025 | Jornay Pm |
| Tris Pharma INC | $140.58 | 2022-2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $139.97 | 2023-2025 | Xelstrym |
| Neos Therapeutics, LP | $119.28 | 2022-2024 | Adzenys Xr-Odt |
| Eisai INC. | $99.73 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $94.10 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $85.82 | 2023-2024 | Horizant, Horizant |
| Idorsia Pharmaceuticals US INC | $84.79 | 2023-2025 | Quviviq, Quviviq |
| Tempus Ai, INC | $40.01 | 2024 | |
| Jazz Pharmaceuticals INC. | $29.98 | 2022 | |
| Adlon Therapeutics L.P. | $14.63 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.16 | 2025 | Spravato |
| Lilly USA, LLC | $13.49 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Clavette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.